News
GRI
0.4100
+0.20%
0.0008
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength to its price action. Tevogen Bio Holdings Inc. Has an RSI value of 19.57.
Benzinga · 4d ago
Weekly Report: what happened at GRI last week (0429-0503)?
Weekly Report · 5d ago
Weekly Report: what happened at GRI last week (0422-0426)?
Weekly Report · 04/29 11:15
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
GRI Bio's abstracts have been accepted for presentation at the 14th International Congress on Autoimmunity being held May 17-20, 2024 in Ljubljana, Slovenia. GRI Bio is advancing an innovative pipeline of Natural Killer T cell modulators for the treatment of autoimmune diseases.
Barchart · 04/29 07:45
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, May 1st at 3:00 PM ET of GRI Bio, Inc. Marc Hertz, PhD, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on May 1, 2024. GRI is a biotechnology company advancing an innovative pipeline of Natural Killer T cell modulators.
Barchart · 04/25 08:15
Weekly Report: what happened at GRI last week (0415-0419)?
Weekly Report · 04/22 11:04
GRI Bio Expands Intellectual Property Protection For Proprietary Natural Killer T Cell Modulators With Issuance Of Korea Patent
Benzinga · 04/16 12:35
Weekly Report: what happened at GRI last week (0408-0412)?
Weekly Report · 04/15 10:56
Weekly Report: what happened at GRI last week (0401-0405)?
Weekly Report · 04/08 11:01
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
GRI Bio's abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA. GRI Bio is advancing an innovative pipeline of Natural Killer T cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases.
Barchart · 04/08 07:35
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. AN2 Therapeutics (NASdaq:ANTX) shares rose by 6.76%. Candel Therapeutic stock moved upwards by 4.99% during the day. Losers AcordaTherapeutics and WAVE Life Sciences lost 8.9% and 7.1% respectively.
Benzinga · 04/04 20:31
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 47.9% to $2.81 during Tuesday's regular session. MSP Recovery (NASdaq:LIFW) shares moved upwards by 33.26%. Q4 earnings report came out 4 days ago. Losers Acorda Therapeutics and Gritstone Bio.
Benzinga · 04/02 16:31
GRI Bio reports FY results
Seeking Alpha · 04/01 14:15
GRI BIO INC - CASH RUNWAY INTO Q3 2024
Reuters · 04/01 11:35
Weekly Report: what happened at GRI last week (0325-0329)?
Weekly Report · 04/01 10:59
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
Barchart · 04/01 06:35
Weekly Report: what happened at GRI last week (0318-0322)?
Weekly Report · 03/25 11:01
Weekly Report: what happened at GRI last week (0311-0315)?
Weekly Report · 03/18 11:00
Weekly Report: what happened at GRI last week (0304-0308)?
Weekly Report · 03/11 10:57
Weekly Report: what happened at GRI last week (0226-0301)?
Weekly Report · 03/04 11:00
More
Webull provides a variety of real-time GRI stock news. You can receive the latest news about GRI Bio through multiple platforms. This information may help you make smarter investment decisions.
About GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).